naporafenib   Click here for help

GtoPdb Ligand ID: 10658

Synonyms: compound 15 [PMID: 31059256] | example 1156 [WO2014151616A1] | LXH-254 | LXH254
PDB Ligand
Compound class: Synthetic organic
Comment: Naporafenib (LXH254) is an investigational, potent, selective and orally bioavailable RAF inhibitor that was designed to target RAS mutant cancers, i.e.those that harbour genetic alterations in the RAS-RAF-MEK-ERK (MAPK) pathway [2]. It is one of the compounds claimed in Novartis' patent WO2014151616A1 [1]. Naporafenib is a Type-2 kinase inhibitor that binds the DFG-out conformation of the kinase.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 96.81
Molecular weight 502.18
XLogP 4.47
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OCCOc1cc(cc(n1)N1CCOCC1)c1cc(ccc1C)NC(=O)c1ccnc(c1)C(F)(F)F
Isomeric SMILES OCCOc1cc(cc(n1)N1CCOCC1)c1cc(ccc1C)NC(=O)c1ccnc(c1)C(F)(F)F
InChI InChI=1S/C25H25F3N4O4/c1-16-2-3-19(30-24(34)17-4-5-29-21(12-17)25(26,27)28)15-20(16)18-13-22(32-6-9-35-10-7-32)31-23(14-18)36-11-8-33/h2-5,12-15,33H,6-11H2,1H3,(H,30,34)
No information available.
Summary of Clinical Use Click here for help
LXH254 has been progressed to Phase 1 clinical studies, and is being evaluated for clinical efficacy against advanced solid tumours with MAPK pathway alterations.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02607813 Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations Phase 1 Interventional Novartis